These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26578082)

  • 1. Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.
    Xu Y; Hackett M; Carter G; Loo C; Gálvez V; Glozier N; Glue P; Lapidus K; McGirr A; Somogyi AA; Mitchell PB; Rodgers A
    Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26578082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
    McGirr A; Berlim MT; Bond DJ; Fleck MP; Yatham LN; Lam RW
    Psychol Med; 2015 Mar; 45(4):693-704. PubMed ID: 25010396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
    Bahji A; Vazquez GH; Zarate CA
    J Affect Disord; 2021 Jan; 278():542-555. PubMed ID: 33022440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials.
    Kryst J; Kawalec P; Mitoraj AM; Pilc A; Lasoń W; Brzostek T
    Pharmacol Rep; 2020 Jun; 72(3):543-562. PubMed ID: 32301056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis.
    Nuñez NA; Joseph B; Pahwa M; Seshadri A; Prokop LJ; Kung S; Schak KM; Vande Voort JL; Frye MA; Singh B
    Psychopharmacol Bull; 2020 Sep; 50(4):137-163. PubMed ID: 33012876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine and depression: a narrative review.
    Corriger A; Pickering G
    Drug Des Devel Ther; 2019; 13():3051-3067. PubMed ID: 31695324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis.
    Lee EE; Della Selva MP; Liu A; Himelhoch S
    Gen Hosp Psychiatry; 2015; 37(2):178-84. PubMed ID: 25698228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.
    Lima TM; Visacri MB; Aguiar PM
    Eur J Clin Pharmacol; 2022 Mar; 78(3):311-338. PubMed ID: 34705064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.
    Witt K; Potts J; Hubers A; Grunebaum MF; Murrough JW; Loo C; Cipriani A; Hawton K
    Aust N Z J Psychiatry; 2020 Jan; 54(1):29-45. PubMed ID: 31729893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
    Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
    J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.